Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Polatuzumab vedotin in relapsed/refractory DLBCL
NCT04182204Phase 3Completed
- Sponsor
- Roche
- Start
- Feb 2020
- Primary completion
- Nov 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 16
01
Overview
A Phase 3 trial of polatuzumab vedotin in diffuse large B-cell lymphoma (DLBCL), sponsored by Roche. Started Feb 2020; status: completed.
02
Drugs
polatuzumab vedotin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04182204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04182204.